Pathogenic Variant in the TAF6 Gene in a Bulgarian Patient with the Ultrarare Alazami-Yuan Syndrome

Abstract

We present a case of a 15-year-old girl, referred for genetic analysis based on clinical evidence of intellectual disability and dysmorphic features with unknown etiology. Following genetic testing, the proband was diagnosed with Alazami-Yuan syndrome (ALYUS). ALYUS is a rare autosomal recessive disorder characterized by developmental delay, intellectual disability, poor speech, and congenital anomalies. Whole-genome sequencing and targeted analysis of 1,610 genes associated with intellectual disability and dysmorphic features were performed. One pathogenic homozygous missense variant in the TAF6 gene was identified (NM_139315.3:c.212T > C, p.Ile71Thr). The finding has been previously reported in scientific publications and detected in individuals with ALYUS. ALYUS occurs phenotypically in the presence of at least two pathogenic variants of the TAF6 gene in either homozygous or compound heterozygous state, regardless of the individual's sex. To date, seven patients from four families have been reported. To our knowledge, our proband is the first individual with ALYUS in Europe and in particular in Bulgaria. Clarification of our patient's genetic diagnosis provided precise genetic counseling for the family, allowed doctors to take appropriate measures for the proband's treatment, and gave options for disease prevention in the future offspring.

Keywords

Alazami-Yuan syndrome - TAF6 gene - intellectual disability - congenital malformations - whole-genome sequencing

Publication History

Received: 22 May 2023

Accepted: 18 July 2023

Article published online:
28 August 2023

• References

• 1 Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: genetic and metabolic testing on children with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2011; 77 (17) 1629-1635
• 2 van Karnebeek CD, Jansweijer MC, Leenders AG, Offringa M, Hennekam RC. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet 2005; 13 (01) 6-25
• 3 Schieppati A, Henter JI, Daina E, Aperia A. Why rare diseases are an important medical and social issue. Lancet 2008; 371 (9629) 2039-2041
• 4 Lugtenberg D, Veltman JA, van Bokhoven H. High-resolution genomic microarrays for X-linked mental retardation. Genet Med 2007; 9 (09) 560-565
• 5 Mefford HC, Batshaw ML, Hoffman EP. Genomics, intellectual disability, and autism. N Engl J Med 2012; 366 (08) 733-743
• 6 Moeschler JB, Shevell M. Committee on Genetics. Comprehensive evaluation of the child with intellectual disability or global developmental delays. Pediatrics 2014; 134 (03) e903-e918
• 7 Richards S, Aziz N, Bale S. et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17 (05) 405-424
• 8 Yuan B, Pehlivan D, Karaca E. et al. Global transcriptional disturbances underlie Cornelia de Lange syndrome and related phenotypes. J Clin Invest 2015; 125 (02) 636-651
• 9 Alazami AM, Patel N, Shamseldin HE. et al. Accelerating novel candidate gene discovery in neurogenetic disorders via whole-exome sequencing of prescreened multiplex consanguineous families. Cell Rep 2015; 10 (02) 148-161
• 10 Accessed August 02, 2023 at: https://www.ncbi.nlm.nih.gov/clinvar/variation/180204
• 11 Chen X, Qi Y, Wu Z. et al. Structural insights into preinitiation complex assembly on core promoters. Science 2021; 372 (6541) eaba8490
• 12 Janssen BDE, van den Boogaard MH, Lichtenbelt K. et al. De novo putative loss-of-function variants in TAF4 are associated with a neuro-developmental disorder. Hum Mutat 2022; 43 (12) 1844-1851
• 13 Mathé G, Schwarzenberg L, Halle-Pannenko O, Simmler MC. Discussion paper: experimental and clinical immunopharmacology data applicable to cancer immunotherapy. Ann N Y Acad Sci 1976; 277 (00) 467-484
• 14 Tuc E, Bengur FB, Aykut A, Sahin O, Alanay Y. The third family with TAF6-related phenotype: Alazami-Yuan syndrome. Clin Genet 2020; 97 (05) 795-796
• 15 Lin SZ, Feng JH, Sun LP, Ma HW, Wang WQ, Li JY. Novel compound heterozygous variants in the TAF6 gene in a patient with Alazami-Yuan syndrome: a case report. World J Clin Cases 2022; 10 (06) 1889-1895